We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA’s “Holding On The Merits” Test

Law360 (April 21, 2006, 12:00 AM EDT) -- In the latest development relating to the triggering of the 180-day generic marketing exclusivity period, the U.S. District Court for the District of Columbia upheld the Food & Drug Administration’s (“FDA”) April 11, 2006 letter ruling, in which FDA adopted a new “holding on the merits” test. In its letter ruling, FDA determined that only a decision on the merits holding the brand company’s patent invalid, unenforceable or not infringed, will trigger the running of the 180-day generic exclusivity period. FDA rejected the argument that a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.